Project Grant R01DK142884
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $480,697 to the Trustees of Indiana University (Indiana University Indianapolis) on March 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The research investigates the role of SESTRIN3 protein in protecting against metabolic dysfunction-associated steatohepatitis (MASH)-related liver fibrosis. The project will characterize SESTRIN3 function and elucidate the...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded $763,766 to Trustees of Indiana University (Indiana University Indianapolis) on August 10, 2026, for Project Grant R01DK149554 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research investigating the role of autophagy dysfunction in type 1 diabetes onset and progression. The project will examine how impaired autophagy in beta cells promotes autoimmune...
- The National Institute of Diabetes and Digestive and Kidney Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $592,746 to Indiana University Indianapolis on June 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on glucose metabolism and skeletal muscle growth. The research will identify glucose transporters activated by mechanical loading in skeletal muscle, determine...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Trustees of Indiana University (Indiana University Indianapolis) $158,036 in a Project Grant on August 17, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds development and pilot testing of four weight stigma reduction intervention components for adolescent-serving clinics, informed by lived experiences of patients and clinical leadership input. The...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Indiana University Indianapolis $149,738 on July 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate transcriptional mechanisms governing beta cell vulnerability in type 1 diabetes. The funded research will elucidate how ZBED family transcription factors regulate beta cell function, immunogenicity, and stress response during autoimmune attack. An in vivo...
- The National Institute of Diabetes and Digestive and Kidney Diseases, a component of the Department of Health and Human Services National Institutes of Health, awarded $674,691 to the Trustees of Indiana University (doing business as Indiana University Indianapolis) on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research investigating alternative splicing of uromodulin (AS-UMOD) as a protective mechanism against...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Duke University $807,500 on August 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project, titled "Decoding the Logic of Metabolite Pool Size Control," develops an integrated metabolic control discovery platform to understand the molecular mechanisms that regulate metabolite concentrations in cells. The research will systematically discover molecular...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The University of Chicago $123,000 on June 16, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to characterize adipocyte heterogeneity and response to metabolic stress. The funded research uses single-nucleus RNA sequencing and a humanized mouse model to investigate how diverse stimuli influence white adipocyte development and specification, with emphasis on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Indiana University Indianapolis $179,551 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to optimize the delivery of obesity treatment through facilitated assessment and selection strategies. The recipient will assess patterns and predictors of individual, combined, and sequential obesity treatment utilization in a statewide cohort; examine patient-,...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Duke University $790,119 on August 26, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how memory formation in adipose tissue influences metabolic outcomes in obesity. The project, titled "Establishing Memory in Adipose Tissue Influences Future Metabolic Outcomes in Obesity," examines the mechanisms that drive divergent remodeling of white...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded Trustees of Indiana University (Indiana University Indianapolis) $743,458 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program on August 10, 2026. The award funds research investigating the role of the SWI/SNF chromatin remodeling complex in adipocyte expansion and its effects on systemic energy and glucose metabolism. The research uses complementary in vitro and in vivo models to elucidate the molecular mechanisms by which a SWI/SNF complex subunit regulates the YAP/TAZ-TEAD pathway through liquid-liquid phase separation and nuclear condensate formation in response to adipocyte expansion during obesity. This work addresses dysfunctional adipose tissue characterization, which underlying impaired lipid metabolism, cell death, and inflammation leading to metabolic diseases including type 2 diabetes and metabolic syndrome. The project period runs from August 10, 2026 through April 30, 2030, with place of performance in Indianapolis, Indiana. The award is a Project Grant, the standard individual research award mechanism under this National Institutes of Health program, which supports extramural basic and clinical biomedical research to improve understanding of disease mechanisms and lead to improved prevention, diagnosis, and treatment across diabetes, digestive, endocrine, metabolic, and related disease areas.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $743.5k | 8/10/26 |